Women's Health

Lenvima (lenvatinib) is approved for the treatment of thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, and endometrial carcinoma.

Teriparatide injection (Forteo) is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture or in patients who have failed or are intolerant to other available osteoporosis therapy.

D-Mannose can aid in maintaining urinary and bladder health.

Uqora Target flushes the urinary tract to help avoid urinary tract infections.

The study has met its primary endpoint, with approximately 78.4% of women who continued taking the drug achieving the sustained responder rate through week 76.

Although the COVID-19 pandemic saw the rapid hemorrhaging of women from careers in science and medicine, research shows the toxicity experienced by women may be structural in nature.

Raloxifene hydrochloride (Evista) is indicated for the treatment and prevention of osteoporosis in postmenopausal women, as well as to lower the risk of invasive breast cancer in postmenopausal women with osteoporosis.

Study findings provide evidence that preventative antibiotics improve health outcomes for babies and mothers, investigator say.

With the new approval, manufacturers believe 7000 new rings will be able to enter the supply chain and will be available to customers in the second and third quarters of 2022.

Here are 9 tips for employers to address employees’ feeling of detachment, exhaustion, and reduced accomplishment.

But HRT is associated with positive changes to cholesterol levels, though the sample size was small, the analysis shows.

Intravenous immunoglobulin shows promise as a treatment option for pregnant patients with SARS-CoV-2, influenza, and other respiratory viruses.

Uristat helps to alleviate symptoms caused by urinary tract infection (UTI), including pain, burning, and needing to urinate urgently.

The advisory, published in Circulation, is a call to action for a cultural shift to identify and remove barriers.

Larger increases were typically seen in states with fewer deaths related to COVID-19, lower unemployment among women, analysis finds.

Investigators develop a genetic-risk score to identify those who would benefit most from lifestyle counseling to prevent the condition.

Findings show that key factors include age, infecting variant, underlying illnesses, and vaccination status.

Legislation allowing pharmacists to prescribe contraceptives is becoming more widespread.

Osteseconazole (Vivjoa) is the first FDA-approved treatment for recurrent vulvovaginal candidiasis, also known as chronic yeast infection, in women with a history of the condition who are not of reproductive potential.

TherapeuticsMD, Inc has submitted a supplemental New Drug Application for estradiol and progesterone capsules 0.5 mg/100 mg (Bijuva) to the FDA.

32 public colleges with combined enrollment of more than 700,000 students must comply with law by January 2023.

Premsyn PMS temporarily relieves symptoms associated with premenstrual syndrome.

Getting an appointment with an infectious diseases specialist, particularly after giving birth and while managing a chronic disorder, such as substance use, is difficult, investigators say.

21-gene profiling is also preferred for patients with 1 to 3 pathologically positive lymph nodes, according to a presentation at the Hematology/Oncology Pharmacy Association conference.

They are also at greater risk of death than men when undergoing cardiac procedures, a new analysis shows.

Pembrolizumab (Keytruda) approved as a single agent for the treatment of patients with microsatellite instability–high or mismatch repair deficient advanced endometrial carcinoma.

Only 40% of patients with platinum sensitive disease are receiving a PARP inhibitor in the first-line setting.

Data from the SOLO-1 trial highlight that even with an excellent prognostic group, patients with ovarian cancer still benefit from the use of a PARP inhibitor.

The death rate from cervical cancer has dropped by more than 50% since 1975.

Use of mirvetuximab soravtansine monotherapy in patients with ovarian cancer resulted in meaningful anti-tumor activity, consistent safety, and favorable tolerability.